F-1/A: Davion Healthcare Files F-1/A for Nasdaq Direct Listing

Davion Healthcare Plc, a pre-revenue company specializing in non-invasive home health tests, filed an amended F-1 registration statement for a direct listing on the Nasdaq Global Market under the symbol DAVI, with commercial product launches expected in H1 2026.

Summary

• Davion Healthcare Plc is pursuing a direct listing of its 25,000,000 ordinary shares on the Nasdaq Global Market under the symbol DAVI.
• The company is pre-revenue, focusing on non-invasive home tests for early detection of health anomalies, including BreastCheck, FootFlow, Testic, and ThermaDerm.
• Its flagship product, BreastCheck, is expected to launch in the USA in the first half of 2026 under a global license agreement with NeuRX Health, Inc.
• The NeuRX agreement includes $120 million in staged license fee payments and minimum annual royalties of $10 million per year over an initial ten-year term.
• The company has incurred operating losses of €0.3 million for the six months ended June 30, 2025, €1.3 million for 2024, and €5.3 million for 2023.
• Davion is dependent on its CEO, Jack Kaye, and his private company Malbrite Ltd, for ongoing financial support to meet working capital requirements and cover expenses.
• The direct listing involves no new share issuance by the company, no underwriter, and no price stabilization; the opening price will be determined by Nasdaq's auction process.
• Directors are subject to a 90-day lock-up, and a majority of shareholders holding over 999 shares have voluntarily agreed to 180-day orderly market sale limitations.
• The company identified a material weakness in internal controls for 2022, 2023, and 2024, leading to restatement of financial statements, and plans to remediate this by hiring additional resources.

Sentiment

Score: 4

Explanation: While the company has innovative products and a significant licensing deal, its pre-revenue status, substantial operating losses, critical dependence on CEO funding, and identified material weaknesses in internal controls present significant financial and operational challenges. The direct listing itself carries high volatility risks due to the absence of traditional underwriting support. The future success hinges entirely on successful product commercialization and market acceptance, which are yet to be proven.

Positives

• Four non-invasive home tests (BreastCheck, FootFlow, Testic, ThermaDerm) are completed and meet Class I regulatory standards (FDA, CE, UKCA).
• Flagship product, BreastCheck, is set for launch in H1 2026 in the USA.
• Secured a global license agreement with NeuRX Health, Inc. for BreastCheck, including $120 million in staged license fees and minimum annual royalties of $10 million per year for ten years.
• The company possesses its own intellectual property, patents, and technology, with no other known competitors attempting to utilize like-technologies.
• Management believes the company has sufficient financial resources for at least the next 12 months, supported by CEO's ongoing financial support and future contractual inflows.
• Appointment of two additional directors, including a Chief Financial Officer and Independent Audit Chair, in December 2025.
• Board of directors will establish audit, compensation, and nominating/corporate governance committees upon listing.

Negatives

• The company is pre-revenue and has incurred significant operating losses: €0.3 million (H1 2025), €1.3 million (2024), and €5.3 million (2023).
• Liquidity is limited, and the company is dependent on its CEO's personal financial support (through Malbrite Ltd) for working capital and expenses.
• Executive officers and directors waived their remuneration in 2025, making current operating results artificially low and not indicative of future cost structure post-listing (annual remuneration of €3.6 million will resume).
• Identified a material weakness in internal controls over financial reporting for 2022, 2023, and 2024, which led to restatement of financial statements.
• The direct listing process lacks traditional IPO safeguards like underwriter price stabilization, bookbuilding, or aftermarket support, potentially leading to high price volatility.
• Existing shareholders will be diluted by the issuance of 125,000 ordinary shares (0.5% of outstanding equity) to the listing advisor, Revere Securities LLC, and potentially by future equity incentive plans or capital raises.
• The company has no full-time or part-time employees, relying on contracted service providers for management functions.

Risks

• Ability to sell ordinary shares at or above purchase price due to direct listing's lack of safeguards, potentially leading to volatile and declining prices.
• Failure of an active, liquid, and orderly market for ordinary shares to develop or be sustained.
• Pre-revenue company with a history of operating losses, dependent on CEO to fund cash needs.
• Operating model relies on a single third-party licensee (NeuRX Health, Inc.) for BreastCheck, exposing the company to risks beyond its control.
• Future growth depends on demand for BreastCheck and consumer adoption.
• Business depends substantially on the continuing efforts of executive officers.
• 2025 operating results are artificially low and not indicative of future cost structure once publicly listed.
• Dilution by future issuances of additional ordinary shares in connection with future business plans.
• Products are subject to government regulations, including HIPAA and FDA compliance in the U.S.
• May not fully recover the value of its intellectual property portfolio.
• Risks related to status as a foreign private issuer and emerging growth company.
• Trading price of ordinary shares may be highly volatile and decline significantly following direct listing.
• Opening auction price may differ significantly from the reference price.
• Nasdaq determines the reference price and opening price independently.
• Absence of underwriter involvement increases risk of price deviation.
• Insufficient buy or sell interest may negatively affect liquidity and trading price.
• Sales of a substantial number of ordinary shares by existing shareholders, or the perception of such sales, could depress the trading price.
• Voluntary orderly market sale agreements are not universal or enforceable by the company, potentially not reducing volatility.
• Lack of an underwriter may result in an unstructured or unstable market.
• Nasdaq may determine the company does not satisfy initial listing requirements, leading to delayed or denied listing or delisting.
• Opening auction may be delayed, negatively affecting market perception.
• Trading may be halted or suspended if Nasdaq detects unusual volatility or order book instability.
• Absence of traditional lock-ups (except for directors/affiliates for 90 days) may increase selling pressure.
• No bookbuilding or institutional price discovery in a direct listing.
• Shareholder sales will drive liquidity and price formation, with low supply reducing liquidity and high supply pressuring price.
• Dependence on licensees exposes the company to significant operational, financial, regulatory, and reputational risks.
• Global or regional licensee underperformance or default could abruptly restrict market access and revenue streams.
• Risk exposure increases when licensees are responsible for warranty obligations and after-sales service.
• Disruptions in licensee manufacturing operations can directly translate to lost product availability.
• Exclusive licensee arrangement structures increase key-partner concentration risk.
• May be forced to assume direct responsibility for manufacturing, sales, distribution, or warranty services if a licensee fails to perform, requiring substantial time and resources.
• Experience cost increases or disruptions in the supply of raw materials (liquid crystal, thermochromic inks/films).
• Dependence on limited or single-source suppliers for product components.
• Business and prospects depend significantly on ability to build and maintain the BreastCheck brand, which may require costly advertising and is vulnerable to negative publicity.
• Initially dependent on a limited number of products (BreastCheck and FootFlow) for revenue.
• Regulatory authorities may reclassify products, increasing costs and delaying commercialization.
• Products are non-diagnostic and may be misunderstood by consumers or healthcare professionals, leading to misuse, reputational damage, and potential liability claims.
• Limited operating history with no commercial sales.
• Revenue may be adversely affected if products are not accepted by consumers and healthcare professionals.
• Failure to manage growth effectively may hinder successful marketing and sales.
• Subject to product liability claims if products do not perform as expected.
• Failure to properly protect and store consumer medical records (PHI) may lead to significant liability, litigation, and reputational harm due to complex and evolving data protection laws (HIPAA, state laws).
• Dependent on third-party mobile platforms (Apple iOS, Google Android) for product functionality, exposing the company to platform requirement changes or application defects.
• Inability to properly maintain technology infrastructure and comply with evolving laws on artificial intelligence use in healthcare could materially and adversely impact the business.
• Limited control over the sales, pricing, and marketing strategies of licensees.
• License agreements may be terminated, and alternative licensees may not be secured timely.
• Licensees may market or develop competing products, reducing focus on Davion's portfolio.
• Failure by partners to meet minimum manufacturing or sales targets may reduce anticipated royalties or milestone payments.
• Disputes with partners could result in costly litigation or arbitration.
• Reliance on third parties creates confidentiality and intellectual property enforcement risks.
• Failure by licensees to maintain adequate product quality and supply may harm reputation.
• Adverse macroeconomic or geopolitical events could affect business.
• If a United States person is treated as owning 10% or more of shares, such holder may be subject to adverse U.S. federal income tax consequences (CFC rules).
• U.S. holders may suffer adverse consequences if the company is treated as a passive foreign investment company (PFIC).
• As an Irish company, investors may face difficulties enforcing their rights due to differences in corporate law.
• Material weakness in internal controls over financial reporting may cause failure to meet reporting obligations or result in material misstatements.
• As an emerging growth company and foreign private issuer, the company may take advantage of reduced reporting requirements, potentially making shares less attractive.

Future Outlook

Davion Healthcare Plc expects to generate its first revenues in the first half of 2026 with the commercial launch of its flagship product, BreastCheck, under a global license agreement with NeuRX Health, Inc. The company anticipates ongoing investments in product development and market entry, with future growth dependent on consumer adoption and successful commercialization of its product portfolio. Management intends to recommend a new equity incentive plan post-listing and may pursue additional capital raises after the direct listing.

Management Comments

• "We believe that we satisfy, or will satisfy prior to the commencement of trading, all applicable quantitative and qualitative initial listing requirements of The Nasdaq Global Market."
• "Our flagship product, BreastCheck, will be the first product to be launched in the first half of 2026."
• "The Company believes as of the date of this Registration Statement, that with its current capitalization, our Chief Executive Officers ongoing financial support, and future contractual inflows, the Company believes that it has sufficient financial resources to meet its obligations for at least the next 12 months."
• "We intend to remediate these weaknesses [material weaknesses in internal controls] by hiring additional resources and modifying our internal and disclosure controls over financial reporting."
• "We currently intend to retain all available funds and any future earnings to fund the development, commercialization and growth of our business, and therefore we do not anticipate declaring or paying any cash dividends on our ordinary shares in the foreseeable future."
• "Our strength as a Company at this early stage is twofold, that we possess our own intellectual property, patents and technology; and that to date, there are no other known competitors attempting to utilize like-technologies."

Industry Context

Davion Healthcare operates in the rapidly evolving Class I medical device industry, focusing on non-invasive home tests for early detection of health anomalies. The company's thermography-based products, combined with AI analysis, aim to address unmet medical needs in areas like breast cancer and diabetic circulation monitoring. The market for breast cancer detection is significant, with millions of new cases globally each year, and the company positions BreastCheck as an adjunct to established procedures like mammograms. The diabetes market also presents a large opportunity for FootFlow, given the high global prevalence of the disease and associated complications like poor circulation. Davion's licensing model allows it to leverage established infrastructure of commercial partners, a common strategy for capital-efficient innovators in the medical device sector, but also introduces dependency risks.

Comparison to Industry Standards

• The company's products meet Class I regulatory standards for non-invasive medical devices in the USA (FDA), Europe (CE), and the UK (UKCA), which is a self-declaration process, indicating a lower regulatory hurdle compared to higher-class devices.
• The direct listing approach, without an underwriter or bookbuilding, deviates significantly from the traditional IPO process, which typically involves price stabilization and institutional investor engagement. This is noted as a risk due to potential higher volatility and uncertain price discovery compared to standard market entry methods.
• The company's reliance on a single third-party licensee (NeuRX Health, Inc.) for manufacturing and distribution of its flagship product, BreastCheck, is a common model in the medical device industry for capital efficiency but contrasts with companies that maintain full control over their supply chain and commercialization.
• The company's pre-revenue status and history of operating losses are typical for early-stage medical technology companies focused on R&D and regulatory approval, but it contrasts with established industry players with diversified revenue streams.
• The valuation reference price of $12 per share for Nasdaq listing requirements is an internal management estimate and not a market-determined price, unlike the pricing in a traditional IPO.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any legal or administrative proceedings and is not aware of any pending or threatened legal or administrative proceedings against it in any material respects.

Related Party Transactions

• Malbrite Ltd (owned by CEO Jack Kaye) provides ongoing financial support, with advances being non-interest-bearing, unsecured, and repayable only upon a future capital raise.
• In 2023, the company acquired intellectual property rights for €65 million from Davion Healthcare Ltd (a UK company), where Jack Kaye was a director and shareholder of both entities. This was a non-cash transaction, with shares issued at €5.30 per share.
• In June 2024, advances from Jack Kaye (through Malbrite Ltd) totaling €4.6 million and €1.0 million in fees due to David Over were converted into 598,246 ordinary shares.
• Management fees of €1.1 million in 2023 were incurred by Malbrite Limited and Kurdam Inc. (controlled by Jack Kaye).
• Director fees of €400,000 (2024) and €600,000 (2023) were incurred by David Over, with the 2024 balance paid in full with share issuances.
• Marketing services of approximately €287,000 in 2023 were paid to Tulk House International Limited (controlled by David Over).
• Management fees of €77,415 in 2023 were incurred by Rallinson Limited (controlled by Jack Kaye).
• Research and development costs of €1,707,178 (2023) were incurred by Rallinson Limited (controlled by Jack Kaye).
• Research and development costs of €556,279 (2023) were incurred by Malbrite Limited (controlled by Jack Kaye).

Stakeholder Impact

• Shareholders: Existing shareholders face potential dilution from the listing advisor's equity fee and future equity incentive plans. The direct listing model may lead to high price volatility and uncertain liquidity, impacting their ability to sell shares at desired prices. The concentration of ownership by executive management and directors (46%) could significantly influence shareholder approval matters.
• Employees (Contracted Management): Executive officers and directors have waived remuneration until listing, indicating a deferred compensation structure that will increase company expenses post-listing.
• Customers: Products are non-diagnostic, and misuse or misunderstanding could lead to adverse outcomes, reputational damage, and potential liability claims. Dependence on third-party mobile platforms and AI infrastructure introduces risks to product functionality and reliability.
• Suppliers: The company's licensed manufacturers are dependent on limited or single-source suppliers for raw materials, creating supply chain disruption risks.
• Creditors: The CEO's company, Malbrite Ltd, is a significant creditor, with advances being unsecured and repayable only upon a future capital raise, indicating a high reliance on related-party financing.

Next Steps

• Commencement of trading on the Nasdaq Global Market under the symbol DAVI.
• Launch of BreastCheck in the USA in the first half of 2026.
• Launch of FootFlow six months after BreastCheck, initially in the USA, then Europe and UK.
• Review of launch dates for ThermaDerm and Testic by management, with regulatory filings established prior to launch.
• Remediation of material weaknesses in internal controls by hiring additional resources and modifying controls.
• Recommendation of a new equity incentive plan for executive officers, independent directors, and third-party service providers by the compensation committee post-listing.
• Potential pursuit of a registered offering or other capital raise following listing.
• Procurement of directors and officers liability insurance prior to commencement of trading.
• Ongoing monitoring of market conditions and licensee performance, with potential to assume direct commercialization responsibilities.
• Continued development of unique home test technologies and filing of additional patent applications.
• Engagement in investor education activities consistent with Nasdaq rules prior to trading.

Key Dates

Recommendation

Davion Healthcare presents a high-risk, high-reward investment profile. The company possesses a portfolio of regulatory-approved, non-invasive home health tests and has secured a substantial licensing agreement with NeuRX Health, Inc., which promises significant future revenue. However, its current pre-revenue status, substantial operating losses, and critical dependence on the CEO's personal funding for ongoing operations are major concerns. The direct listing itself introduces significant market volatility risks due to the absence of traditional underwriting support. While the long-term potential of its innovative products in large markets is attractive, the immediate financial fragility and execution risks warrant a 'hold' recommendation. Investors should await evidence of successful product launches, consistent revenue generation, and a reduction in reliance on related-party financing before considering a more aggressive stance.

Keywords

Davion Healthcare, DAVI, Direct Listing, Nasdaq, SEC F-1/A, Healthcare Technology, Non-invasive Tests, BreastCheck, FootFlow, Testic, ThermaDerm, Medical Devices, Class I Medical Device, FDA, CE Mark, UKCA, Thermography, AI in Healthcare, Licensing Model, NeuRX Health, Pre-revenue, Operating Losses, Corporate Governance, Risk Factors, Intellectual Property, HIPAA Compliance, Capital Raise, Ireland Company, Foreign Private Issuer, Emerging Growth Company